Cargando…

Fucose as a new therapeutic target in renal transplantation

Ischaemia/reperfusion injury (IRI) is an inevitable and damaging consequence of the process of kidney transplantation, ultimately leading to delayed graft function and increased risk of graft loss. A key driver of this adverse reaction in kidneys is activation of the complement system, an important...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Mark C, Nauser, Christopher L, Vizitiu, Daniela A, Sacks, Steven H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009799/
https://www.ncbi.nlm.nih.gov/pubmed/32472330
http://dx.doi.org/10.1007/s00467-020-04588-2
_version_ 1783672946119671808
author Howard, Mark C
Nauser, Christopher L
Vizitiu, Daniela A
Sacks, Steven H
author_facet Howard, Mark C
Nauser, Christopher L
Vizitiu, Daniela A
Sacks, Steven H
author_sort Howard, Mark C
collection PubMed
description Ischaemia/reperfusion injury (IRI) is an inevitable and damaging consequence of the process of kidney transplantation, ultimately leading to delayed graft function and increased risk of graft loss. A key driver of this adverse reaction in kidneys is activation of the complement system, an important part of the innate immune system. This activation causes deposition of complement C3 on renal tubules as well as infiltration of immune cells and ultimately damage to the tubules resulting in reduced kidney function. Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of complement. CL-11 binds to a ligand that is exposed on the renal tubules by the stress caused by IRI, and through attached proteases, CL-11 activates complement and this contributes to the consequences outlined above. Recent work in our lab has shown that this damage-associated ligand contains a fucose residue that aids CL-11 binding and promotes complement activation. In this review, we will discuss the clinical context of renal transplantation, the relevance of the complement system in IRI, and outline the evidence for the role of CL-11 binding to a fucosylated ligand in IRI as well as its downstream effects. Finally, we will detail the simple but elegant theory that increasing the level of free fucose in the kidney acts as a decoy molecule, greatly reducing the clinical consequences of IRI mediated by CL-11.
format Online
Article
Text
id pubmed-8009799
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80097992021-04-16 Fucose as a new therapeutic target in renal transplantation Howard, Mark C Nauser, Christopher L Vizitiu, Daniela A Sacks, Steven H Pediatr Nephrol Review Ischaemia/reperfusion injury (IRI) is an inevitable and damaging consequence of the process of kidney transplantation, ultimately leading to delayed graft function and increased risk of graft loss. A key driver of this adverse reaction in kidneys is activation of the complement system, an important part of the innate immune system. This activation causes deposition of complement C3 on renal tubules as well as infiltration of immune cells and ultimately damage to the tubules resulting in reduced kidney function. Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of complement. CL-11 binds to a ligand that is exposed on the renal tubules by the stress caused by IRI, and through attached proteases, CL-11 activates complement and this contributes to the consequences outlined above. Recent work in our lab has shown that this damage-associated ligand contains a fucose residue that aids CL-11 binding and promotes complement activation. In this review, we will discuss the clinical context of renal transplantation, the relevance of the complement system in IRI, and outline the evidence for the role of CL-11 binding to a fucosylated ligand in IRI as well as its downstream effects. Finally, we will detail the simple but elegant theory that increasing the level of free fucose in the kidney acts as a decoy molecule, greatly reducing the clinical consequences of IRI mediated by CL-11. Springer Berlin Heidelberg 2020-05-29 2021 /pmc/articles/PMC8009799/ /pubmed/32472330 http://dx.doi.org/10.1007/s00467-020-04588-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Howard, Mark C
Nauser, Christopher L
Vizitiu, Daniela A
Sacks, Steven H
Fucose as a new therapeutic target in renal transplantation
title Fucose as a new therapeutic target in renal transplantation
title_full Fucose as a new therapeutic target in renal transplantation
title_fullStr Fucose as a new therapeutic target in renal transplantation
title_full_unstemmed Fucose as a new therapeutic target in renal transplantation
title_short Fucose as a new therapeutic target in renal transplantation
title_sort fucose as a new therapeutic target in renal transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009799/
https://www.ncbi.nlm.nih.gov/pubmed/32472330
http://dx.doi.org/10.1007/s00467-020-04588-2
work_keys_str_mv AT howardmarkc fucoseasanewtherapeutictargetinrenaltransplantation
AT nauserchristopherl fucoseasanewtherapeutictargetinrenaltransplantation
AT vizitiudanielaa fucoseasanewtherapeutictargetinrenaltransplantation
AT sacksstevenh fucoseasanewtherapeutictargetinrenaltransplantation